Esperite strengthens Genoma, its Genomics company with Dr Thomas Rio Frio, NGS specialist and Senior Geneticist.

PRESS RELEASE

Zutphen, The Netherlands, 18 September 2014

Esperite NV (Euronext.: ESP, 'Esperite' or 'the Group'), the European leader in stem cells cryopreservation, now entering the fields of predictive medicine and translational regenerative medicine R&D, announces the appointment of Dr. Thomas Rio Frio as Genomics Manager of its business unit Genoma.

Thomas Rio Frio holds a MSc from the University of Nantes, France and a Ph.D. in Human Molecular Genetics from the University of Lausanne, Switzerland. He brings an extensive experience in next-generation sequencing (NGS) and molecular techniques as well as a deep knowledge of human and cancer genetics to Genoma. Most recently he was NGS platform manager at Institut Curie in Paris where he established a cutting-edge NGS platform and completed more than 100 NGS projects during the last 18 months. Before this, he developed serveral genetic tests for IntegraGen SA in Paris in his function as Senior Geneticist. He is now in charge to set-up and manage an in-house genomics platform to run the Tranquility Test, the most reliable non-invasive prenatal test on the market to detect fetal chromosomal abnormalities through a single blood draw from the mother, and to translate research findings of clinical importance into screening and predictive genetic tests to help people to live a healthier life..

Frederic Amar, Chief Executive Officer, commented:

"Genoma is delighted with this strong addition to its team. Mr. Rio Frio's appointment underlines the company's strategic direction to become a strong player in the fields of proteomics and genomics predictive medicine. His extensive experience is a strong asset for Genoma's global activities."

Cryo-Save, the leading international stem cell processing and cryo-conservation company and the largest family stem cell bank in Europe continues to increase its sales force coverage in several markets. The launch of new promotional materials and a new innovative and improved collection kit reinforce the communication directly to end clients.

The Cell Factory, the Group's R&D division, is focusing an important part of its regenerative medicine activities on investigating clinical trial opportunities for the treatment of cerebral palsy and other neurological disorders. The development of new technologies for stem cell bioproduction from cord blood and cord tissue will play a major role in future therapeutic approaches.

Enquiries:

Esperite	+ 31 (0) 575 548 998
Frederic Amar, Chief Executive Officer

Contact details                                    
For more information on Esperite visit  www.esperite.com
Esperite N.V.                                       
Piet Heinstraat 11a                                
7204 JN Zutphen
The Netherlands
Tel. [phone]
Fax [phone]
  
Esperite, the leading international company in regenerative and predictive medicine. Its family stem cell bank, CryoSave, stores more than 268,000 samples from umbilical cord blood and cord tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Esperite has cryopreserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Switzerland, Germany, Dubai, South Africa and Portugal.

---

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Esperite N.V. via Globenewswire

HUG#1856713